According to filings with the U.S. Securities and Exchange Commission, TETmedical is raising up to $9,812,108.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About TETmedical
TETmedical, Inc. (Tethered Enzyme Technologies) is a clinical-stage platform nanomedicine company focused on developing in vitro diagnostic tests that enable rapid, high-sensitivity decision making for high-consequence diseases, beginning with acute stroke. Its patented TET nanobot technology consists of thousands of enzymes tethered to a silica nanoparticle in a miniature molecular machineless than a hundredth the width of a human hairdesigned to perform chemical operations with far greater speed and stability than traditional antibody assays. The companys first product, the Neuron Specific Enolase Functional Activity Stroke Test (NSE-FAST), is an enzyme-based blood test intended to be the first in-vitro diagnostic for brain injury from stroke, fitting into standard emergency department workflows and aiming to ensure that no acute ischemic strokes are missed, an area of significant unmet clinical need. Emerging from groundbreaking research at Cornell University by Professors Alex Travis and Roy Cohen, TETmedical applies its tethered enzyme platform to the detection of diverse biomarkers including proteins, enzymes, viruses, and microRNAsand is also advancing additional applications such as at-home liver function testing and ultra-rapid, sensitive nucleic-acid assays for viral and other pathogens. The company is supported by substantial grant funding from NIH and New York State and continues clinical feasibility and regulatory work toward FDA De Novo approval for NSE-FAST, positioning itself as a pioneering player in nanomedicine-powered precision diagnostics.

To learn more, visit https://tetmedical.com/
LinkedIn: https://www.linkedin.com/company/tetmedical/

Contact:
David Fischell, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.